Original articles
Jing Jin, Nina Xue, Yuan Liu, Rong Fu, Mingjin Wang, Ming Ji, Fangfang Lai, Jinping Hu, Xiaojian Wang, Qiong Xiao, Xiaoying Zhang, Dali Yin, Liping Bai, Xiaoguang Chen, Shuan Rao. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models[J]. Acta Pharmaceutica Sinica B, 2020, 10(2): 276-288

A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models
Jing Jina, Nina Xuea, Yuan Liub, Rong Fua, Mingjin Wanga, Ming Jia, Fangfang Laia, Jinping Hua, Xiaojian Wanga, Qiong Xiaoa, Xiaoying Zhanga, Dali Yina, Liping Baic, Xiaoguang Chena, Shuan Raob
a State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China;
b Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;
c State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute, for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR 999078, China
Abstract:
Psoriasis is characterized by abnormal proliferation of keratinocytes, as well as infiltration of immune cells into the dermis and epidermis, causing itchy, scaly and erythematous plaques of skin. The understanding of this chronic inflammatory skin disease remains unclear and all available treatments have their limitations currently. Here, we showed that IMMH002, a novel orally active S1P1 modulator, desensitized peripheral pathogenic lymphocytes to egress signal from secondary lymphoid organs and thymus. Using different psoriasis animal models, we demonstrated that IMMH002 could significantly relieve skin damage as revealed by PASI score and pathological injure evaluation. Mechanistically, IMMH002 regulated CD3+ T lymphocytes re-distribution by inducing lymphocytes' homing, thus decreased T lymphocytes allocation in the peripheral blood and skin but increased in the thymus. Our results suggest that the novel S1P1 agonist, IMMH002, exert extraordinary capacity to rapidly modulate T lymphocytes distribution, representing a promising drug candidate for psoriasis treatment.
Key words:    S1P1    S1P1 agonist    IMMH002    Lymphocyte    Psoriasis   
Received: 2019-06-19     Revised: 2019-10-16
DOI: 10.1016/j.apsb.2019.11.006
Funds: This work is supported by the CAMS Innovation Fund for Medical Sciences (2016-I2M-3-008, China), National Natural Science Foundation of China (NSFC Nos. 81872923 and 81473096), Beijing Natural Science Foundation (No. 7172140, China) and The Drug Innovation Major Project (No. 2018ZX09711001-003, China).
Corresponding author: Jing Jin, Xiaoguang Chen, Shuan Rao     Email:rebeccagold@imm.ac.cn;chxg@imm.ac.cn;raoshuan1@smu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Jing Jin
Nina Xue
Yuan Liu
Rong Fu
Mingjin Wang
Ming Ji
Fangfang Lai
Jinping Hu
Xiaojian Wang
Qiong Xiao
Xiaoying Zhang
Dali Yin
Liping Bai
Xiaoguang Chen
Shuan Rao

References:
1. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers 2016;2:16082.
2. Rapp SR, Feldman SR, Exum ML, Fleischer Jr AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
3. Chiricozzi A, Saraceno R, Novelli L, Fida M, Caso F, Scarpa R, et al. Small molecules and antibodies for the treatment of psoriasis:a patent review (2010-2015). Expert Opin Ther Pat 2016;26:757-66.
4. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis:review of current data. Br J Dermatol 2012;167 Suppl 3:3-11.
5. Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market. Nat Rev Drug Discov 2015;14:745-6.
6. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009;78:743-68.
7. Kwong E, Li Y, Hylemon PB, Zhou H. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B 2015;5:151-7.
8. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005;108:308-19.
9. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-59.
10. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018;45:264-72.
11. Malakouti M, Brown GE, Wang E, Koo J, Levin EC. The role of IL-17 in psoriasis. J Dermatol Treat 2015;26:41-4.
12. AbuHilal M, Walsh S, Shear N. The role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis. J Cutan Med Surg 2016;20:509-16.
13. Suzuki S, Li XK, Shinomiya T, Enosawa S, Amemiya H, Amari M, et al. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin Exp Immunol 1997;107:103-11.
14. Matsuura M, Imayoshi T, Chiba K, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 2000;49:404-10.
15. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101.
16. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720):discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-97.
17. Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis:a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet 2014;384:2036-45.
18. Ryan C, Menter A. Ponesimodda future oral therapy for psoriasis?. The Lancet 2014;384:2006-8.
19. Ji M, Xue N, Lai F, Zhang X, Zhang S, Wang Y, et al. Validating a selective S1P1 receptor modulator Syl930 for psoriasis treatment. Biol Pharm Bull 2018;41:592-6.
20. Tian Y, Jin J, Wang X, Hu J, Xiao Q, Zhou W, et al. Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design. Eur J Med Chem 2014;85:1-15.
21. Mi J, Zhao M, Yang S, Yang S, Jin J, Wang X, et al. Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatography-tandem mass spectrometry. Acta Pharm Sin B 2016;6:576-83.
22. Tian Y, Jin J, Wang X, Han W, Li G, Zhou W, et al. Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1-phosphate 1(S1P1) receptor. MedChemComm 2013;4:1267.
23. Talmadge JE, Jackson JD, Borgeson CD, Perry GA. Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following splitdose polychemotherapy. Cancer Immunol Immunother 1994;39:59-67.
24. Wang H, Jiang M, Cui H, Chen M, Buttyan R, Hayward SW, et al. The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol 2012;32:3190-202.
25. Jin J, Hu J, Zhou W, Wang X, Xiao Q, Xue N, et al. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochem Pharmacol 2014;90:50-61.
26. Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005;111:222-9.
27. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010;53:4198-211.
28. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307.
29. Telo I, Pescina S, Padula C, Santi P, Nicoli S. Mechanisms of imiquimod skin penetration. Int J Pharm 2016;511:516-23.
30. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645-53.
31. Diani M, Altomare G, Reali E. T helper cell subsets in clinical manifestations of psoriasis. J Immunol Res 2016;2016:7692024.
32. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004;309:758-68.
33. Milara J, Navarro R, Juan G, Peiro T, Serrano A, Ramon M, et al. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax 2012;67:147-56.
34. Murakami K, Kohno M, Kadoya M, Nagahara H, Fujii W, Seno T, et al. Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model. PLoS One 2014;9. e106792.
35. Gendron DR, Lemay AM, Lecours PB, Perreault-Vallieres V, Huppe CA, Bosse Y, et al. FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycininduced lung injury. Pulm Pharmacol Ther 2017;44:50-6.
36. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V, et al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Investig 2011;121:2290-300.
37. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012;167:1035-47.
38. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9.
39. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-36.
40. Hamada M, Nakamura M, Kiuchi M, Marukawa K, Tomatsu A, Shimano K, et al. Removal of sphingosine 1-phosphate receptor-3(S1P3) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P1 agonists with reduced effect on heart rate. J Med Chem 2010;53:3154-68.
41. Fryer RM, Muthukumarana A, Harrison PC, Nodop Mazurek S, Chen RR, Harrington KE, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat. PLoS One 2012;7. e52985.
42. Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, et al. Discovery of BAF312(siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett 2013;4:333-7.
43. Nishi T, Miyazaki S, Takemoto T, Suzuki K, Iio Y, Nakajima K, et al. Discovery of CS-0777:a potent, selective, and orally active S1P1 agonist. ACS Med Chem Lett 2011;2:368-72.
44. Komiya T, Sato K, Shioya H, Inagaki Y, Hagiya H, Kozaki R, et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol 2013;171:54-62.
45. Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One 2018;13. e0193236.
46. Ueyama A, Yamamoto M, Tsujii K, Furue Y, Imura C, Shichijo M, et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse:a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol 2014;41:135-43.
47. Takagi H, Arimura K, Uto T, Fukaya T, Nakamura T, Choijookhuu N, et al. Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation. Sci Rep 2016;6:24477.
48. Han Y, Li X, Zhou Q, Jie H, Lao X, Han J, et al. FTY720 abrogates collagen-induced arthritis by hindering dendritic cell migration to local lymph nodes. J Immunol 2015;195:4126-35.
49. Idzko M, Hammad H, van Nimwegen M, Kool M, Müller T, Soullié T, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Investig 2006;116:2935-44.
50. Lan YY, De Creus A, Colvin BL, Abe M, Brinkmann V, Coates PT, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005;5:2649-59.